6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
6m ago	Hovnanian Enterprises Reports Fiscal 2026 Second Quarter Results
6m ago	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
6m ago	KKR Sells CIRCOR Aerospace to Parker Hannifin for $2.55 Billion
7m ago	Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
7m ago	Intuitive Announces Innovations to Advance Quintuple Aim

About

5.97USD+0.31 +5.48%

Closed • Updated at 13:22 GMT+00:00

Market Cap$308.63M

Volume2.25M

Beta1.87

RSI30.14

Gross Margin50.52%

Health TechnologyPharmaceuticals: Major

Regenxbio Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Community Chat

Ask AI